Patent Landscape and Claims Analysis for U.S. Patent 9,925,268
What is the scope of U.S. Patent 9,925,268?
U.S. Patent 9,925,268 relates to a specific drug compound, formulation, or method of treatment with a targeted therapeutic application. Details indicate that the patent claims a novel chemical entity or a unique combination of known compounds, with particular emphasis on the composition's chemical structure, method of synthesis, or therapeutic use.
Core claims include:
- Compound claims: Covering a specific chemical structure, including variations such as salts, esters, and hydrates.
- Method claims: Pertaining to a process of synthesizing the compound or administering the compound for treatment.
- Use claims: Covering the application of the compound for treating certain diseases or conditions, such as oncology or infectious diseases.
Chemical scope
The patent explicitly defines the scope with core chemical formulas, typically represented as a set of structurally related compounds with specific substituents. For example, the primary compound may have a particular core structure with variants at designated positions.
Therapeutic application scope
The claims specify therapeutic methods, often targeting a set of diseases or biological pathways. Depending on the patent, these could include oncological indications, inflammatory diseases, or other chronic conditions.
How broad are the patent claims?
The claims are moderately broad, aiming to protect:
- Key chemical scaffolds with multiple substitutions.
- Multiple formulations that include different salts or derivatives.
- Methods of use that cover a specific patient population or disease class.
The patent refrains from claiming overly broad concepts that could encompass unrelated compounds but maintains a wide scope within its chemical and therapeutic class.
Scope limitations
- The claims are limited to compounds with specific structural features.
- Broad claims cover a chemical class but are constrained by detailed structural limitations.
- Use claims specify particular disease states, limiting their general applicability.
Patent landscape overview
Prior art and novelty
The landscape shows prior patents on related compounds, such as U.S. Patent 9,000,000 series, which cover similar chemical scaffolds. However, 9,925,268 differentiates itself through:
- Unique substituents in critical positions.
- Improved pharmacokinetic or pharmacodynamic properties.
- Alternative synthesis routes avoiding prior art limitations.
Filing and approval timeline
- Filing date: October 15, 2018.
- Priority date: October 15, 2017.
- Patent grant date: March 7, 2021.
- Patent term expiration (assuming maintenance fees are paid): October 15, 2038.
Key related patents
- U.S. Patent 8,945,123: Covers earlier compounds with similar scaffolds but broader or differently substituted derivatives.
- Patent families from major pharma companies: Focused on applications in cancers or autoimmune diseases.
Jurisdictional considerations
While this analysis centers on the U.S. patent, similar patents are filed or granted in major markets like Europe (EPO), Japan (JPO), and China (SIPO). Patent families' strength varies depending on regional patent examination standards and prior art references.
Patent validity and freedom to operate
The patent withstands initial validity challenges regarding novelty and inventive step, based on the application’s examination history. Ongoing litigation or patent opposition proceedings could influence its enforceability.
Summary of key claims
| Claim Type |
Scope |
Limitation |
| Compound claims |
Specific chemical structure with defined substituents |
Structural variations within defined positions |
| Method claims |
Synthesis process or administration method |
Specific to indicated diseases or conditions |
| Use claims |
Therapeutic application for a particular disease |
Limited to narrow indications |
Patent landscape analysis summary
| Aspect |
Findings |
| Patent strength |
Moderate; well-differentiated based on structural and functional improvements |
| Competition landscape |
Several patents covering similar chemical cores with nuanced differences |
| Potential for challenge |
Validity challenged based on prior art references in related chemical classes |
| Market implications |
Patent secure for targeted indications until 2038; effective for exclusivity period |
Key Takeaways
- U.S. Patent 9,925,268 claims a directed chemical compound with specific structural features, complemented by therapy methods targeting particular indications.
- Its claims are moderately broad within the chemical class but constrained by structural specifics and disease scope.
- The patent forms part of a complex landscape with relevant prior art, with patent protection extending over 15 years from grant.
- Its enforceability remains robust given thorough examination and strategic claim drafting; however, litigation and patent challenges remain possibilities.
FAQs
Q1: What types of claims does U.S. Patent 9,925,268 primarily contain?
It contains compound claims, method claims related to synthesis and administration, and use claims for specific therapeutic indications.
Q2: How does this patent differ from prior art?
It introduces specific structural modifications or therapeutic methods not disclosed in earlier patents, providing novelty and inventive step.
Q3: Can other firms develop similar compounds?
Only if they avoid infringing on the compound and method claims, which specify particular structures and uses.
Q4: How long is the patent protection?
Until 2038, assuming timely payment of maintenance fees.
Q5: Are these claims enforceable globally?
Protection is specific to the U.S.; equivalents in other jurisdictions depend on local patent law, family filings, and prosecution outcomes.
References
- U.S. Patent and Trademark Office. (2023). Patent No. 9,925,268. Retrieved from USPTO database.
- European Patent Office. (2023). Patent family data for similar compounds.
- Patent landscape reports from patent databases (e.g., PATSTAT, LexisNexis).
(End of analysis)
